Results 171 to 180 of about 54,287 (293)

Controlled Substance Lock-In Programs: Examining An Unintended Consequence Of A Prescription Drug Abuse Policy. [PDF]

Health Aff (Millwood), 2016
Roberts AW, Farley JF, Holmes GM, Oramasionwu CU, Ringwalt C, Sleath B, Skinner AC.   +6 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source

Interprofessional Research, Training and Outreach: The ETSU Prescription Drug Abuse/Misuse Working Group. [PDF]

Int J Health Sci Educ, 2016
Pack RP, Hagaman A, Warfield S, Gray JA, Tudiver F, Alamian A, Hagemeier NE.   +6 more
europepmc   +1 more source

Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5‐Year Follow‐Up

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction We aimed to investigate the risks of all‐cause and cause‐specific mortality associated with dose‐dependent benzodiazepine and Z‐drug (BZDR) use in the Finnish population initiating new BZDR use with five‐year follow‐up. Methods Study subjects were included if BZDR use had started in 2006 with no BZDR dispensing during the ...
Hanna Särkilä, Heidi Taipale, Antti Tanskanen, Tero Taiminen, Reijo Sund, Terhi Kurko, Jarmo Hietala, Solja Niemelä   +7 more
wiley   +1 more source

Prescription drug usage on the rise among women.

, 2011
THE HSE HAS been asked to investigate prescription practises for certain medications after a national study showed a “huge increase” in the usage of legally available opiates. Women and people aged between 25 – 34 are most likely to consume such drugs,

core  

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data

Addiction, Volume 120, Issue 4, Page 745-755, April 2025.
Abstract Aims The aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.
Allison M. McFall, Lakshmi Ganapathi, Mihili P. Gunaratne, Aylur K. Srikrishnan, Conjeevaram K. Vasudevan, Santhanam Anand, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas   +8 more
wiley   +1 more source

Adolescent Prescription Drug Abuse: An Overview of Current Data

, 2013
Prescription drug abuse among adolescents is a growing and increasingly lethal problem. Recent survey studies show a concerning increase in abuse and poor awareness among users, parents, and medical providers.
Cowan, Tavis
core  

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source